Pandion Therapeutics Inc.

$PAND

IPO Year: 2020

Exchange: NASDAQ

Recent Analyst Ratings for Pandion Therapeutics Inc.

DatePrice TargetRatingAnalyst
See more ratings

Pandion Therapeutics Inc. Press Releases

Fastest customizable press release news feed in the world

See more
  • Merck Completes Acquisition of Pandion Therapeutics

    KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp

  • Merck Begins Tender Offer to Acquire Pandion Therapeutics

    KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND). On Feb. 25, 2021, Merck announced its intent to acquire Pandion. Upon the successful closing of the tender offer, stockholders of Pandion will receive $60 in cash for each share of Pandion common stock validly tendered and not validly withdrawn in the offer, without interest and less any required withholding taxes. Following the purchase of shares in the tender offer, Pandion will become a subsidiary of Merck. Merck will

    $MRK
    $PAND
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Merck to Acquire Pandion Therapeutics

    KENILWORTH, N.J & WATERTOWN, Mass.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Pandion Therapeutics, Inc. (Nasdaq: PAND) today announced that the companies have entered into a definitive agreement, under which Merck, through a subsidiary, will acquire Pandion, a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, for $60 per share in cash. This represents an approximate total equity value of $1.85 billion. “This acquisition builds upon Merck’s strategy to identify and secure candidates with differentiated and potentially foundational charac

    $MRK
    $PAND
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting

    WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today presented preclinical data on PT001, the Company’s tissue-tethered PD-1 agonist, at the Network for Pancreatic Organ Donors with Diabetes (nPOD) 13th Annual Scientific Meeting. The research, done in collaboration with St Vincent’s Institute of Medical Research in Australia and funded by JDRF and the JDRF T1D Fund, showed that PT001 treatment delayed the onset of hyperglycemia in a mouse model of Type 1 diabetes. PD-1 plays a critical role in

  • Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference

    WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced that Rahul Kakkar, M.D., Chief Executive Officer of Pandion Therapeutics, will present at the upcoming 10th Annual SVB Leerink Healthcare Conference on Thursday, February 25, 2021, at 9:20 a.m. ET. A live webcast of the presentation will be available in the Investors and News section of Pandion Therapeutics’ website at https://www.pandiontx.com/. A replay of the webcast will be available shortly following the presentation. About Pa

  • Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells

    -Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in third-party clinical trials across multiple autoimmune diseases-PT101 maintained selectivity for regulatory T cells at all doses tested-Phase 1a/2b clinical trial in ulcerative colitis expected to start mid-2021 and Phase 2 clinical trial in systemic lupus erythematosus expected to start second half 2021-Phase 1a results to be presented in a conference call scheduled today at 8:30 a.m. ET WATERTOWN, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics (Nasdaq: PAND) today announced positive to

  • NodThera Appoints Chief Medical Officer and Chief Financial Officer

    CAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer. Dr. Johns is an accomplished drug development leader and board-certified clinical neurologist who previously served as Chief Medical Officer and Executive Vice President of Medical and Scientific Affairs at Syntimmune, prior to the company’s acquisition by Alexion Pharmaceuticals. Ms. Dorton is a recognized

    $PAND
    $FULC
    $ECOL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Environmental Services
    Public Utilities
  • Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

    WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expe

    $PAND
    $ECOL
    $MS
    $FULC
    Environmental Services
    Public Utilities
    Investment Bankers/Brokers/Service
    Finance

Pandion Therapeutics Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

Pandion Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

Pandion Therapeutics Inc. SEC Filings

See more

Pandion Therapeutics Inc. Leadership Updates

Live Leadership Updates

See more
  • NodThera Appoints Chief Medical Officer and Chief Financial Officer

    CAMBRIDGE, England & BOSTON & SEATTLE--(BUSINESS WIRE)--NodThera, a biotechnology company developing a new class of medicines that inhibit the NLRP3 inflammasome to treat chronic inflammation, today announced the expansion of its senior leadership team with the appointments of Donald Johns, M.D., as Chief Medical Officer and Katina Dorton, J.D., MBA, as Chief Financial Officer. Dr. Johns is an accomplished drug development leader and board-certified clinical neurologist who previously served as Chief Medical Officer and Executive Vice President of Medical and Scientific Affairs at Syntimmune, prior to the company’s acquisition by Alexion Pharmaceuticals. Ms. Dorton is a recognized

    $PAND
    $FULC
    $ECOL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Environmental Services
    Public Utilities
  • Pandion Therapeutics Appoints Katina Dorton to its Board of Directors

    WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet needs of patients living with autoimmune diseases, today announced the appointment of Katina Dorton, J.D., M.B.A., to Pandion’s board of directors and as chair of the audit committee. Ms. Dorton assumes the position of chair of the audit committee from Christopher Fuglesang, Ph.D., J.D., who will continue to serve as a member of the board and audit committee. Mitchell Mutz, Ph.D., resigned from the Company’s board on December 2, 2020. “Ms. Dorton brings to Pandion over two decades of financial expe

    $PAND
    $ECOL
    $MS
    $FULC
    Environmental Services
    Public Utilities
    Investment Bankers/Brokers/Service
    Finance

Pandion Therapeutics Inc. Financials

Live finance-specific insights

See more
  • Merck Completes Acquisition of Pandion Therapeutics

    KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Pandion Therapeutics, Inc. (Nasdaq: PAND) at a purchase price of $60 per share. As of the tender offer expiration, 27,770,123 shares of common stock of Pandion were validly tendered and not withdrawn from the tender offer, representing approximately 88.6% percent of the outstanding common stock of Pandion on a fully diluted basis. All such shares have been accepted for payment in accordance with the terms of the tender offer, and Merck exp

Pandion Therapeutics Inc. Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more